FRATES JAMES M
Chief Financial Officer
FRATES JAMES M has filed 7 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Sep 14, 2026.
On the most recent filing, FRATES JAMES M is listed as Chief Financial Officer at Amylyx Pharmaceuticals, Inc. Inside the rolling window, FRATES JAMES M reported no open-market purchases and 5 open-market sales totaling $708K in AMLX. The largest disclosed transaction in the window is a sale of 10,810 AMLX shares on Sep 10, 2026, worth $350K.
Companies traded
Other insiders at AMLX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$708K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has FRATES JAMES M made?
FRATES JAMES M has filed 7 SEC Form 4 filings (8 transaction rows) across 1 company since 2025.
Which companies does FRATES JAMES M trade?
FRATES JAMES M has filed SEC Form 4 disclosures for 1 company, including AMLX.
When was FRATES JAMES M's most recent SEC Form 4 filing?
FRATES JAMES M's most recent SEC Form 4 filing on Tracefour is dated Sep 14, 2026.
What is FRATES JAMES M's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, FRATES JAMES M is listed as Chief Financial Officer.
What is FRATES JAMES M's total buy and sell value in the current window?
Inside the rolling retention window, FRATES JAMES M bought $0 and sold $708K based on SEC Form 4 filings.
What was FRATES JAMES M's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,810 AMLX shares on 2026-09-10, worth $350K, per SEC Form 4 filings.